Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Peanut Immunotherapy (University Hospital, Geneva) is an allergen-specific immunotherapy (AIT) consisting of a subcutaneous injection of peanut extract. Developed by the University Hospital, Geneva, this treatment was investigated in a Phase 1/2 pilot study (NCT00107796) to evaluate its safety and efficacy in children and adults with persistent peanut allergy. The protocol involved bi-weekly injections over a three-month period. The therapy aims to induce immunological tolerance by modulating the immune system's response to peanut proteins, specifically by promoting the production of regulatory T cells and allergen-specific IgG4 antibodies while reducing IgE-mediated mast cell and basophil activation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Peanut Immunotherapy (University Hospital, Geneva).